Role of the transcription factor Ets-1 in cisplatin resistance

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 823-832

  Wilson, Leigh A ^a   Yamamoto, Hirotaka ^b   Singh, Gurmit ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Chicago Institute of Neurosurgery and Neuroresearch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; CELL LINE; CELL SPECIFICITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR RESISTANCE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION;

EID: 4444328522     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumour platinum drugs. Drug Resist Updat 2002;5:147-61.
2. Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs 1993;46:360-77.
3. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7255-79.
4. Rosell R, Lord RVN, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002;38:217-27.
5. Holford J, Beale PJ, Boxall FE, Sharp SY, Kelland LR. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000;36:1984-90.
6. Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 2001;59: 837-43.
7. Hagrman D, Goodisman J, Dabrowiak JC, Souid AK. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 2003; 31:916-23.
8. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
9. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-3.
10. Andrews PA, Velury S, Mann SC, Howell SB. cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988;48:68-73.
11. Bergoglio V, Canitrot Y, Hogarth L, et al. Enhanced expression and activity of DNA polymerase β in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene 2001;20:6181-7.
12. Mann SC, Andrews PA, Howell SB. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1990;25:236-40.
13. Moorehead RA, Armstrong SG, Rainbow AJ, Singh, G. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). Cancer Chemother Pharmacol 1996; 38:245-53.
14. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
15. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
16. Deng HB, Parekh HK, Chow KC, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 2002;277:15035-43.
17. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001; 168:173-81.
18. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278:19245-56.
19. Andrews PA, Albright KD. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 1992;52:1895-901.
20. Zinkewich-Peotti K, Andrews PA. Loss of cis-diamminedichloroplatinum (II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992;52:1902-6.
21. Moorehead RA, Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000;59:337-45.
22. Logan SK, Garabedian MJ, Campbell CE, Werb Z. Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem 1996;271:774-82.
23. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene 2000;19:6464-71.
24. Wernert N, Raes MB, Lassalle P, et al. c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992; 140:119-27.
25. Span PN, Manders; P, Heuvel JJ, et al. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002;21:8506-9.
26. Davidson B, Reich R, Goldberg I, et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001;7:551-7.
27. Wernert N, Gilles F, Fafeur V, et al. Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 1994;54: 5683-8.
28. Nakada M, Yamashita J, Okada Y, Sato H. Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. J Neuropathol & Exp Neurol 1999;58:329-34.
29. Yamamoto H, Swoger J, Greene S, et al. β1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity. Cancer Res 2000;60:134-42.
30. Kitange G, Shibata S, Tokunaga Y, et al. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab Invest 1999;79:407-16.
31. Yasuda M, Ohzeki Y, Shimizu S, et al. Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Life Sci 1999;64:249-58.
32. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2001;289:39-43.
33. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-tos mRNA reduces expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991;88:10591-5.
34. Futami H, Shiotani T, Yamaji Y, Yamauchi N, Irino S. Effects of the combination of acivicin and cis-diamminedichloroplatinum (II) on thymidylate synthesis of A549 lung cancer cells. Biochem Biophys Res Commun 1989;161:31-7.
35. Dong S, Lester L, Johnson LF. Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter. J Cell Biochem 2000;77:50-64.
36. Pan B, Yao KS, Monia BP, et al. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem Pharmacol 2002;63:1699-707.